ERBB2 and neoplasm: To evaluate the biodistribution and the pharmacokinetics of the novel immunoconjugate, the pre-“clicked” [111In]In-DO3A-BODIPY-Tz-TCO-trastuzumab conjugate was evaluated in vivo employing the traditional targeted approach in SKOV-3 (human HER2-positive) tumor bearing mice.